Search clinical trials for: foretinib

Total 8 results

NCIC Clinical Trials Group
GlaxoSmithKline

Completed

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Breast Cancer

Canada
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197)

Recurrent Breast Cancer

Canada
GlaxoSmithKline

Completed

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Carcinoma, Renal Cell

United States
GlaxoSmithKline

Completed

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Neoplasms, Head and Neck

United States
GlaxoSmithKline

Completed

Study of GSK1363089 in Metastatic Gastric Cancer

Neoplasms, Gastrointestinal Tract

United States
GlaxoSmithKline

Completed

Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

Carcinoma, Hepatocellular

Taiwan, Thailand, Hong Kong
GlaxoSmithKline

Withdrawn

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Cancer

3

Subscribe